Setback in Prostate Cancer Trial: CAPItello-280 Study for Truqap Discontinued
/in Clinical Trial, Metastatic, Phase 3/by MaxUPDATE: ATNM-400 a Promising Antibody Radioconjugate Delivering 225 Ac
/in Preclinical Research/by MaxOST11098: A Promising New Approach for Castration-Resistant Prostate Cancer
/in Preclinical Research/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: NXP900 for Overcoming Resistance in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- New PSMA Radiohybrid Combines PET Imaging With Alpha Therapy October 14, 2026
- Phase 2 Trial Tests Tinengotinib With Darolutamide or Enzalutamide in Hormone-Resistant Prostate Cancer October 13, 2026
- Phase 1 Trial Investigates MAO-A Inhibition With ITR-251 to Overcome Prostate Cancer Resistance October 13, 2026
- Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer October 13, 2026